Literature DB >> 21411374

Atrioventricular block following lacosamide intoxication.

Lars U Krause1, Kai O Brodowski, Christoph Kellinghaus.   

Abstract

Lacosamide (LCM) is a novel anticonvulsant that modulates voltage-dependent sodium channels. Although it is known to cause a slight, dose-dependent prolongation of the PR interval on the ECG, third-degree atrioventricular (AV) block has been described as an adverse event in only a few patients participating in diabetic neuropathic pain studies and in no patient with epilepsy. We describe an 89-year old patient with decreased renal function and taking two other negative dromotropic agents who accidentally received two intravenous boli of 400 mg LCM within 6 hours. She had a normal PQ interval before and after the first dose of LCM and developed a reversible complete AV block approximately 30 minutes after the second bolus. We conclude that particular caution must be exercised when using very high doses of LCM in patients with significant cardial and renal risk factors.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411374     DOI: 10.1016/j.yebeh.2011.02.006

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  14 in total

1.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Safety and Efficiency of Intravenous Push Lacosamide Administration.

Authors:  K Erin Davidson; Joshua Newell; Khalid Alsherbini; Joseph Krushinski; G Morgan Jones
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

Review 3.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

4.  Lacosamide: a Study of Exposures Reported to US Poison Centers over a 9-Year Period.

Authors:  John Teijido; Derek Kempf; Elizabeth Laubach; Amy Zosel; Douglas Borys
Journal:  J Med Toxicol       Date:  2019-07-08

Review 5.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

Review 6.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

7.  Use of lacosamide in children with refractory epilepsy.

Authors:  Marcia L Buck; Howard P Goodkin
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

8.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

9.  Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis.

Authors:  Makoto Shibata; Reona Hoshino; Chisato Shimizu; Masayuki Sato; Natsumi Furuta; Yoshio Ikeda
Journal:  BMC Neurol       Date:  2021-06-08       Impact factor: 2.474

Review 10.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.